A national survey of 1,100 bladder cancer patients found nearly 80% reported fear of recurrence, rising to over 90% among those under 50. Many respondents underwent five or more cystoscopies, with some facing more than 15 procedures over their disease course, underscoring the chronic surveillance burden.

UroGen’s proprietary RTGel sustained-release hydrogel is designed to extend urinary tract tissue exposure to therapeutics, potentially reducing the frequency of invasive interventions. The platform’s ability to deliver localized therapy over time could address both tumor control and long-term quality of life concerns highlighted by the survey.

UroGen provided financial backing for the survey to better understand patient experiences and inform product development. The findings may shape future clinical strategies and underscore potential market demand for treatments that minimize procedural burden in non-muscle invasive bladder cancer.